Tickets are NOW ON SALE for our Spring Ethics & GCP Forum at University College London on Friday 19th April. Lord O'Shaughnessy will be presenting in person! So book early to avoid disappointment!…
Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting …
The National Institute for Health and Care Research (NIHR) has awarded over £20m to eight new global health research projects to strengthen health service delivery and resilience in low- and middle-in…
AstraZeneca is working with the NHL to encourage people to “Get Body Checked Against Cancer.” The campaign is designed to encourage sports fans to ask their doctors about available cancer screenings a…
Since 2022, an estimated 17,000 strokes and 4,000 deaths have been prevented
The NHS has revealed that thousands of lives have been saved and around 17,000 strokes prevented due to the rapid roll-out …
Jardiance development partners Eli Lilly and Boehringer Ingelheim say it takes two: two tests, to be exact, to find out about a patient’s kidney disease.
That sparked a memory, one going all the way b…
The world we’re living in is changing rapidly and the future of health is being profoundly shaped by several interconnected factors.
The media marketplace’s shifting dynamics have reached tectonic proportion with reshuffles at emergent platforms and effects of union strikes shaking up media’s Grand Dame – Hollywood. Despite the myr…
By early December, the Food and Drug Administration will decide on approval of a genetic medicine for sickle cell disease, potentially offering people with the rare blood condition a new, sought-after…
With the nights drawing in, Bausch Health is taking the plunge on the first-ever TV spot for its seasonal affective disorder (SAD) drug Aplenzin. The ad is designed to encourage people who withdraw, o…
NPIP will transform medical research and provide better outcomes for patients
The Medicines Discovery Catapult (MDC), the Medical Research Council (MRC) and Innovative UK has announced the launch of t…
Astellas’ mission to turn menopause drug Veozah into a major product is ratcheting up a gear, with the drugmaker hitting go on a TV spot centered on how the recently approved therapy turns hot flashes…
In an era characterised by remarkable breakthroughs in drug discovery, development and biotech innovation, many say we’re in the midst of a …
The evolution of clinical research has been dependent on the conversion of Healthcare Organizations (HCOs) to clinical research sites, along with the conversion of Healthcare Providers (HCPs) to Princ…
Pharma has changed a lot in recent years. The rules and regulations surrounding develo…
Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as part of a corporate rebranding in th…
The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
MSD has revealed that the National Institute for Health and Care Excellence (NICE) has recommended the use of …
It was only last spring that Biogen started a round of layoffs that eventually shrank the company’s head count by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions …
Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue
The Norfolk and Norwich University Hospitals (NNUH) Urology team have become the first in the East of England…
To book via Eventbrite and see the full agenda visit our Website
If you have any questions please email office@icr-global.org
Reef Group and UBS Asset Management have gained approval to develop one of Europe’s largest life sciences campuses in Stevenage, UK.
The family of Henrietta Lacks is suing rare disease drug developer Ultragenyx over its use of technology built from her cells, which were taken without her knowledge or consent in 1951 and immortalize…
Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it…
For those of us who use sophisticated digital tools every day, it’s easy to assume that technology always makes life easier. It doesn’t.
TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial.
The study measured the effect of hydromethylthionine mes…